ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
A Generative Neuro-Symbolic AI for Protein Sequence Design.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Deep learning has revolutionized computational protein design, enabling the generation of sequences that fold onto target backbones with unprecedented accuracy. However, state-of-the-art inverse folding tools largely rely on auto-regressive sampling. While powerful, this paradigm is increasingly recognized for its inability to "think ahead", a crucial capacity to reliably create the complex, long-range inter-residue dependencies essential for most biological functions. To overcome these fundamental limitations, we introduced EffieDes, a generative neuro-symbolic AI framework that synergizes the predictive capabilities of deep learning with the logical precision of automated reasoning. EffieDes leverages deep learning to encode the target backbone's fitness landscape into Effie-a fully decomposable probabilistic graphical model (Potts model). This landscape can then be rigorously explored by an automated reasoning prover to identify sequences that simultaneously satisfy complex design constraints and optimize backbone fitness. We validated this neuro-symbolic approach through the design of orthogonal sequence pairs that adopt identical folds but exhibit selective self-assembly, as well as the design of a de novo selective nanobody with nanomolar affinity for an immune-evasive SARS-CoV-2 variant. EffieDes provides a robust architecture for precisely dissecting learned fitness landscapes, offering a new path toward proteins with highly optimized performances and sophisticated functional objectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.